ESC 365 - Levosimendan use in anthracycline-induced cardiomyopathy: reversing the irreversible ?

HFA Premium Access

Levosimendan use in anthracycline-induced cardiomyopathy: reversing the irreversible ?

Session: Cardio-oncology 3

Topic: Cardio-Oncology

Speaker: Doctor V. Tassi (Athens, GR)

Event: Heart Failure 2024

Congress Presentation

Add to my library

About the speaker

Doctor Vasiliki Tassi

Evangelismos Hospital, Athens (Greece)

2 presentations

0 follower

4 more presentations in this session

Cardiotoxicity due to combined target therapy of malignant melanoma with full recovery after its discontinuation

Speaker: Doctor V. Dimitrova (Sofia, BG)

Multidisciplinary approach in cardio-oncology: putting words into action

Speaker: Doctor A. Pons Riverola (Barcelona, ES)

Immune checkpoint inhibitor-associated myocarditis: a rare presentation with electrical storm in a young patient with Hodgkin lymphoma

Speaker: Doctor A. Stavrati (Thessaloniki, GR)

Anthracycline chemotherapy-related cardiac dysfunction? It is not always what it seems

Speaker: Doctor H. Morillas Climent (Barcelona, ES) Doctor S. Jimenez-Marrero (Barcelona, ES)

Access the full session

Cardio-oncology 3

Speakers: Doctor V. Tassi, Doctor V. Dimitrova, Doctor A. Pons Riverola, Doctor A. Stavrati, Doctor H. Morillas Climent...

About the event

Heart Failure 2024

11 May - 14 May 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources